title: Antinociceptive mechanisms of orally administered decursinol in the mouse.
abstract: Antinociceptive profiles of decursinol were examined in ICR mice. Decursinol administered orally (from 5 to 200 mg/kg) showed an antinociceptive effect in a dose-dependent manner as measured by the tail-flick and hot-plate tests. In addition, decursinol attenuated dose-dependently the writhing numbers in the acetic acid-induced writhing test. Moreover, the cumulative response time of nociceptive behaviors induced by an intraplantar formalin injection was reduced by decursinol treatment during the both 1st and 2nd phases in a dose-dependent manner. Furthermore, the cumulative nociceptive response time for intrathecal (i.t.) injection of TNF-alpha (100 pg), IL-1 beta (100 pg), IFN-gamma (100 pg), substance P (0.7 microg) or glutamate (20 microg) was dose-dependently diminished by decursinol. Intraperitoneal (i.p.) pretreatment with yohimbine, methysergide, cyproheptadine, ranitidine, or 3,7-dimethyl-1-propargylxanthine (DMPX) attenuated inhibition of the tail-flick response induced by decursinol. However, naloxone, thioperamide, or 1,3-dipropyl-8-(2-amino-4-chloro-phenyl)-xanthine (PACPX) did not affect inhibition of the tail-flick response induced by decursinol. Our results suggests that decursinol shows an antinociceptive property in various pain models. Furthermore, antinociception of decursinol may be mediated by noradrenergic, serotonergic, adenosine A(2), histamine H(1) and H(2) receptors.
authors.affiliation: Department of Pharmacology, College of Medicine, and Institute of Natural Medicine, Hallym University, 1 Okchun-dong, Chunchon, Kangwon Do, 200-702, South Korea.
authors.forename: Seong-Soo
authors.initials: SS
authors.lastname: Choi
authors.forename: Ki-Jung
authors.initials: KJ
authors.lastname: Han
authors.forename: Jin-Koo
authors.initials: JK
authors.lastname: Lee
authors.forename: Han-Kyu
authors.initials: HK
authors.lastname: Lee
authors.forename: Eun-Jung
authors.initials: EJ
authors.lastname: Han
authors.forename: Do-Hoon
authors.initials: DH
authors.lastname: Kim
authors.forename: Hong-Won
authors.initials: HW
authors.lastname: Suh
mesh_terms: D000284:Administration, Oral; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000700:Analgesics / Q000494:pharmacology*; D000818:Animals; D001578:Benzopyrans / Q000008:administration & dosage* / Q000494:pharmacology*; D002087:Butyrates / Q000008:administration & dosage* / Q000494:pharmacology*; D003533:Cyproheptadine / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D018698:Glutamic Acid / Q000494:pharmacology; D006635:Histamine H2 Antagonists / Q000494:pharmacology; D007371:Interferon-gamma / Q000494:pharmacology; D007375:Interleukin-1 / Q000494:pharmacology; D008297:Male; D008784:Methysergide / Q000494:pharmacology; D051379:Mice; D008813:Mice, Inbred ICR; D008956:Models, Chemical; D009270:Naloxone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D010146:Pain / Q000188:drug therapy*; D010880:Piperidines / Q000494:pharmacology; D011493:Protein Kinase C / Q000037:antagonists & inhibitors; D011899:Ranitidine / Q000494:pharmacology; D011941:Receptors, Adrenergic / Q000378:metabolism; D011968:Receptors, Histamine / Q000378:metabolism; D018047:Receptors, Purinergic P1 / Q000378:metabolism; D011985:Receptors, Serotonin / Q000378:metabolism; D012702:Serotonin Antagonists / Q000494:pharmacology; D013373:Substance P / Q000494:pharmacology; D013805:Theobromine / Q000031:analogs & derivatives* / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology; D014970:Xanthines / Q000494:pharmacology; D015016:Yohimbine / Q000494:pharmacology
chemical_list: D000317:Adrenergic alpha-Antagonists; D000700:Analgesics; D001578:Benzopyrans; D002087:Butyrates; D006635:Histamine H2 Antagonists; D007375:Interleukin-1; D009292:Narcotic Antagonists; D010880:Piperidines; D011941:Receptors, Adrenergic; D011968:Receptors, Histamine; D018047:Receptors, Purinergic P1; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D014409:Tumor Necrosis Factor-alpha; D014970:Xanthines; D015016:Yohimbine; D003533:Cyproheptadine; D013373:Substance P; D009270:Naloxone; D018698:Glutamic Acid; C057837:3,7-dimethyl-1-propargylxanthine; D007371:Interferon-gamma; D011899:Ranitidine; C101278:decursin; D011493:Protein Kinase C; C046379:1,3-dipropyl-8-(2-amino-4-chlorophenyl)xanthine; C052075:thioperamide; D013805:Theobromine; D008784:Methysergide